Design, Construction and Cloning of Truncated ORF2 and tPA<sub>sp</sub>-PADRE-Truncated ORF2 Gene Cassette From Hepatitis E Virus in the pVAX1 Expression Vector

Fatemeh Farshadpour<sup>1,2</sup>, Manoochehr Makvandi<sup>2</sup>, and Reza Taherkhani<sup>1,3</sup><sup>*</sup>

<sup>1</sup>Department of Microbiology and Parasitology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IR Iran
<sup>2</sup>Health Research Institute, Infectious and Tropical Disease Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
<sup>3</sup>Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, IR Iran

*Corresponding author: Reza Taherkhani, Department of Microbiology, School of Medicine, Bushehr University of Medical Sciences, Moallem St., Bushehr, IR Iran. Tel: +98-9171712653, Fax: +98-77125220814, E-mail: taherkhanireza2005@yahoo.com

Received 2014 December 18; Revised 2015 September 4; Accepted 2015 September 20.

Abstract

**Background:** Hepatitis E Virus (HEV) is the causative agent of enterically transmitted acute hepatitis and has high mortality rate of up to 30% among pregnant women. Therefore, development of a novel vaccine is a desirable goal.

**Objectives:** The aim of this study was to construct tPA<sub>sp</sub>-PADRE-truncated open reading frame 2 (ORF2) and truncated ORF2 DNA plasmid, which can assist future studies with the preparation of an effective vaccine against Hepatitis E Virus.

**Materials and Methods:** A synthetic codon-optimized gene cassette encoding tPA<sub>sp</sub>-PADRE-truncated ORF2 protein was designed, constructed and analyzed by some bioinformatics software. Furthermore, a codon-optimized truncated ORF2 gene was amplified by the polymerase chain reaction (PCR), with a specific primer from the previous construct. The constructs were sub-cloned in the pVAX1 expression vector and finally expressed in eukaryotic cells.

**Results:** Sequence analysis and bioinformatics studies of the codon-optimized gene cassette revealed that codon adaptation index (CAI), GC content, and frequency of optimal codon usage (Fop) value were improved, and performance of the secretory signal was confirmed. Cloning and sub-cloning of the tPA<sub>sp</sub>-PADRE-truncated ORF2 gene cassette and truncated ORF2 gene were confirmed by colony PCR, restriction enzymes digestion and DNA sequencing of the recombinant plasmids pVAX-tPA<sub>sp</sub>-PADRE-truncated ORF2<sub>(aa 112-660)</sub> and pVAX-truncated ORF2<sub>(aa 112-660)</sub>. The expression of truncated ORF2 protein in eukaryotic cells was approved by an Immunofluorescence assay (IFA) and the reverse transcriptase polymerase chain reaction (RT-PCR) method.

**Conclusions:** The results of this study demonstrated that the tPA<sub>sp</sub>-PADRE-truncated ORF2 gene cassette and the truncated ORF2 gene in recombinant plasmids with different formulations will be evaluated as a novel DNA vaccine in future investigations.

**Keywords:** Hepatitis E Virus, ORF2 Protein, PADRE Peptide, Signal Sequence, DNA Vaccine

1. Background

Hepatitis E Virus (HEV) has been classified to the Orthohepevirus A species, Orthohepevirina genus and Hepeviridae family. This virus causes acute but self-limited hepatitis in the general population (1, 2). Infection with HEV ranges from moderate to severe hepatitis, yet severity of the disease increases with age (1, 2). The mortality rate can range between 25 to 33% in pregnant women, particularly during the third trimester of pregnancy (1, 3), and 30 to 70% in individuals with chronic liver disease (1, 4). No specific treatment exists for acute hepatitis E, and no protective vaccine against HEV infection has been licensed (1, 5). Therefore, development of an effective vaccine against HEV infection is the only alternative approach to prevent its spread. At present, molecular approaches are the main focus of vaccine design, since there are no appropriate and effective culture systems for HEV replication (6). There are three overlapping open reading frames (ORF1, ORF2 and ORF3) in the genome of HEV (7). The ORF2 gene encodes capsid protein of 72 kDa, which has 660 amino acids (1, 7). The capsid protein has been studied for HEV vaccine development, as it is highly conserved and immunodominant among HEV species, and induces longstanding immunity (6, 8). In addition, antibodies against capsid protein neutralize HEV in vitro, and protect primates against HEV infection (8, 9). This suggests that ORF2 protein could be used as a suitable antigen in serological test kits for the diagnostic and seroepidemiological surveillance of HEV infection (2, 10), and also as promising a vaccine candidate against HEV infection in humans (11). The 112 to 660 residue of ORF2 protein self-assembles into virus-like particles (VLPs) and initiates strong immune responses (12). However, when the full-length cap-

---

Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in non-commercial usages, provided the original work is properly cited.
sid protein is expressed, its immunogenic properties are masked due to insolubility. Therefore, most efforts to develop vaccines against HEV infection have focused on the truncated or short forms of the capsid protein (5, 13). Up to now, full-length and various truncated forms (112 - 660 aa, 112 - 607 aa, 368 - 606 aa and 458 - 607 aa) of ORF2 have been used in several DNA vaccine studies (14 - 16). Since the time of DNA vaccine innovation, several strategies have been introduced to improve vaccine potency such as co-administration of different adjuvants, codon optimization of the gene, or using plasmids encoding a secreted form of the protein. Codon usage frequency is different among various organisms. Therefore, codon optimization can result in high expression of the desired gene similar to the host cell genes, whose expression levels are high. The mRNA secondary structures that have a negative effect on the translation efficiency are reduced or removed by codon optimization (17-19). In vaccination with recombinant DNA, the processing and presentation of antigens are improved, since the native form of antigens are expressed in cells, and can usually activate both arms of the immune system (14, 16, 20). DNA vaccines can be formulated to target specific cell compartments for antigenic processing. However, plasmids encoding a secreted form of the target protein, by fusing it to the signal sequence of human tissue plasminogen activator (tPA), are generally more immunogenic, for both B and T cells, than plasmids encoding a non-secreted form (21, 22). A universal Pan HLA-DR (allelic DR) epitope peptide, named PADRE, has been described previously, which is capable of binding promiscuously to variants of the human major histocompatibility complex (MHC) class II molecules DR with high-affinity and is effective in both humans and mice (23). The PADRE HTL epitope was used as an adjuvant to increase the Cytotoxic T lymphocyte (CTL) responses (24). Based on this evidence, herein, we designed and constructed two DNA plasmids encoding tPA-PADRE-truncated ORF2 gene cassette and truncated ORF2 gene. The novel chimerical pVAX-tPA-PADRE-truncated ORF2 plasmid carries the secretory signal sequence derived from human tissue Plasminogen Activator (tPA) and PADRE sequence fused at the N-terminus of the truncated form of the HEV ORF2 gene.

2. Objectives

In the present study, the tPA-PADRE-truncated ORF2 optimized gene cassette and truncated ORF2 optimized gene from Hepatitis E Virus were cloned in the pVAXi expression vector separately, and transfected into HEK293 cells and Chinese Hamster Ovary (CHO) eukaryotic cells. Furthermore, the main goal of the present study was to construct the recombinant plasmids pVAX-tPA-PADRE-truncated ORF2 and pVAX-truncated ORF2 as DNA vaccine candidates.

3. Materials and Methods

3.1. Bacterial Hosts, Plasmid, Eukaryotic Cells and Culture Conditions

Escherichia coli strain DH5α (Novagen Inc., Madison, Wis., USA) was used for transformation and the pVAX1 plasmid (Invitrogen®, Carls-bad, CA, USA) was used for subcloning of the truncated ORF2 and tPAsp-PADRE-truncated ORF2 (112 - 660 aa) gene cassette. Eukaryotic expression vector, pVAXi, was constructed to be consistent with the Food and Drug Administration (FDA) regulations. HEK293 cells, routinely maintained in our laboratory, and CHO cell line, purchased from the national cell bank of Iran (Pasteur Institute), were used for protein expression. All kits were purchased from the Qiagen company (Germany); T4 DNA ligase and restriction endonucleases were purchased from New England Biolabs (New England Biolabs Inc., USA). All chemicals were purchased from Merck (Germany) and Sigma-Aldrich Corporation (Germany).

3.2. Design, Optimization and in Silico Analysis of tPAsp-PADRE-Truncated ORF2 Gene Cassette of Hepatitis E Virus and de novo Synthesis

The 112 - 660 amino acid sequence of ORF2 gene of Hepatitis E virus genotype 1 (Sar55 strain) was retrieved from UniProtKB/Swiss-Prot databases (Pakistan/Sar-55 strain, accession number P33426) and entered in the Vector NTI software (Vector NTI software version Advance® 11.5, Invitrogen). Next, the following sequences were added to the N-terminal of the truncated ORF2 gene (aa 112-660); Primarily, the 22-amino-acid-sequence (MDAMKRGLCCVLLCGAVFVSP) of the secretory peptide of human tissue-type plasminogen activator protein, (tPAsp signal peptide) was retrieved from http://www.signalpeptide.de/ and UniProtKB/Swiss-Prot databases (Accession no. P33426) and entered in the Vector NTI software. In the next step, PADRE 13-amino acid sequence (Pan HLA DR-reaction epitope) that is the universal epitope of T lymphocyte (CD4+ T cell epitope), AKFVAAWTLKAAA, was placed after the secreted peptide sequence. All Sequences were back translated to sequence of nucleotides using Vector NTI (Vector NTI software version Advance® 11.5, Invitrogen). The reverse translation used the most abundant codon for each amino acid, found in a compendium of highly expressed mouse genes. Finally, the complete kozak sequence, GCCGCCACCATGG, was added to increase the efficiency of translation initiation. Two restriction enzyme digestion sites, including NheI and XhoI, were placed in the tPA-PADRE-truncated ORF2 gene cassette for sub-cloning into the pVAXi vector. Arrangement of fragment junctions is shown in Figure 1. Also to ensure the accuracy of the cloning process, virtual cloning was performed using the clone Manager software (Clone Manager Professional 9, USA) in pVAXi eukaryotic expression plasmid.
To optimize the gene cassette, the in silico analysis was performed using online data bases such as codon adaptation index calculation (http://genomes.urv.es/CAIcal/), Analysis of Codon Usage (http://codonw.sourceforge.net), Codon Database (http://www.kazusa.or.jp/codon), Codon-Adaptation Tool (http://www.jcat.de/), signal peptide analysis (http://www.cbs.dtu.dk/services/SignalP/), and Leto (Entelechon, Germany). The gene cassette was then analysis using GenScript rare codon analysis tool software (www.genscript.com) was used for expression in mouse cells and submitted to GenScript for more optimization and verification using the GenScript’s OptimumGene gene design tool (GenScript Inc., NJ, USA). This software optimizes a variety of parameters that are critical for efficiency of gene expression such as codon usage, eliminates immature polyadenylation sites, splicing sites, killer motifs, repeated sequences and RNA secondary structure, and also avoids excessive local content of GC or AT. Following verification of the construct’s properties, the optimized tPA<sub>sp</sub>-PADRE-truncated ORF2 gene cassette was then synthesized and cloned into the pBMH commercial cloning vector by Biomatik Company (Biomatik Corporation, Cambridge, Canada).

### 3.3. Sub-Cloning of Codon-Optimized tPA<sub>sp</sub>-PADRE-Truncated ORF2 Gene Cassette in pVAX1 Eukaryotic Expression Vector

To sub-clone the optimized tPA<sub>sp</sub>-PADRE-truncated ORF2 gene cassette into pVAX1 eukaryotic expression vector, the recombinant plasmid pBMH-tPA<sub>sp</sub>-PADRE-truncated ORF2<sub>(aa 112-660)</sub> and the pVAX1 plasmid were separately digested by NheI and XhoI restriction enzymes. After analysis on agarose gel and colony PCR method and restriction digestion with NheI and XhoI enzymes. Next, the recombinant plasmids with the correct restriction pattern were used for DNA sequencing with the T7 forward and BGH reverse primers (Bioneer, Korea), to corroborate proper orientation of the cloned gene cassette. The confirmed construct was named pVAX-tPA<sub>sp</sub>-PADRE-truncated ORF2<sub>(aa 112 - 660)</sub>.

### 3.4. Generation of a Codon-optimized Truncated ORF2 Gene and Cloning in pVAX1 Eukaryotic Expression Vector

The gene fragment encoding truncated ORF2<sub>(aa 112 - 660)</sub> gene (without tPA secretory signal and PADRE sequence) was PCR amplified using Q5 High-Fidelity DNA Polymerase (New England Biolabs, USA). Sequence of the forward primer, which includes a Kozak consensus sequence, was 5’-AACCTAGGCTAGCCGCCACCATGGCGGTGGCCCCCGCTCACGACA-3’, and sequence of the reverse primer was 5’-ACGGGCCCTCTAGACTCGAGTCATCAGAATTCTCA-3’. This gene was directly cloned into pVAX1, using restriction sites NheI and XhoI. After analysis of the truncated ORF2<sub>(aa 112 - 660)</sub> PCR product by agarose gel electrophoresis, the specific band was extracted from 1% agarose gel using the QIAquick® Gel Extraction Kit (Qiagen, Germany), according to the manufacturer’s instructions. The purified PCR product and the pVAX1 plasmid were digested by NheI and XhoI restriction enzymes, extracted from LMP agarose gel, and purified fragments were used for ligation by T4 DNA ligase. The recombinant plasmids were electroporated into E. coli DH5α cells. Cloning of truncated ORF2 gene in pVAX1 was verified using enzyme digestion, colony PCR by universal primers (T7, BGH) and finally sequencing. The confirmed construct was named pVAX-truncated ORF2<sub>(aa 112 - 660)</sub>.

---

**Figure 1. Schematic Model of the Recombinant tPA<sub>sp</sub>-PADRE-Truncated ORF2 Gene Cassette and Truncated ORF2 Gene**

Legend:
- **PADRE Sequence**
- **tPA Signal Peptide**
- **Kozak Sequence**
- **NheI (2)**
- **XhoI (1791)**
- **Xmal (1762)**
- **Stop Coden**
- **Eco RI (1779)**

---

**Farshadpour F et al.**

*Jundishapur J Microbiol. 2015;8(12):e26035*
3.5. Expression of Recombinant tPAsp-PADRE-Truncated ORF2 and Truncated ORF2 in Mammalian Cells

The recombinant plasmids pVAX-tPA<sub>sp</sub>-PADRE-truncated ORF2 and pVAX-truncated ORF2, were extracted by the Plasmid Purification Midi Kit with transfection grade according to the manufacturer’s instructions (Qiagen, Germany). To evaluate expression of recombinant proteins in eukaryotic cells, ultrapure expression plasmids containing truncated ORF2 were transfected in HEK-293 and CHO cells by X-tremeGENE 9 DNA transfection reagent (Roche, Germany), according to the manufacturer’s instructions. Furthermore, HEK-293 and CHO cells as expression organisms were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (GIBCO-BRL) supplemented with 10% fetal bovine serum (FBS), in the presence of gentamycin (50 µg/mL) and amphotericin B (2.5 µg/mL) (GIBCO-BRL) at 37°C with 5% CO₂, then transiently transfected with either recombinant plasmids or pVAX in six-well culture plates (Nunc, Denmark). After 48 hours, mRNA of truncated ORF2 gene was determined by RT-PCR in transfected cells. In brief, total cellular RNA was extracted by the RNeasy Mini Kit (Qiagen, Germany), and RT-PCR was then performed using a QIAGEN One Step RT-PCR Kit (Qiagen, Germany), according to the manufacturer’s protocol by specific primers (upstream primer: F1478 5’- ACCACAGCCAGTGATCAGC-3’ and downstream primer: R1730 5’-TCATCTTCAGCCTCTG</p>
Figure 2. Bioinformatics Analysis of tPA_{Ap}PADRE-Truncated ORF2 Gene Cassette

A. Codon Adaptation Index (CAI) of the non-optimized and optimized truncated ORF2 gene; B. GC content of the non-optimized and optimized truncated ORF2 gene; C. Frequency of optimal codons (FOP) of the non-optimized and optimized truncated ORF2 gene; D. Presence (left picture) and absence (right picture) of 22-amino acid secretory peptide before and after addition to truncated ORF2 protein using the signal peptide analysis online software.
Figure 3. A, Sub-cloning Results of Optimized tPA<sub>sp</sub>-PADRE-Truncated ORF2 (aa 112 - 660) Gene Cassette In Pvax1 Eukaryotic Plasmid; Lane M, 1kb DNA marker; Lane 1, pBMH-tPA<sub>sp</sub>-PADRE-truncated ORF2 plasmid; Lane 2, digested pBMH-tPA<sub>sp</sub>-PADRE-truncated ORF2 plasmid by NheI restriction enzyme; Lane 3, digested pBMH-tPA<sub>sp</sub>-PADRE-truncated ORF2 plasmid by NheI and XhoI restriction enzymes and production of two expected fragments, a 2909-bp and a 1795-bp fragment; Lane 4, pVAX plasmid; Lane 5, digested pVAX plasmid by NheI and XhoI restriction enzymes and production of 2909-bp band; Lane 6, pVAX-tPA<sub>sp</sub>-PADRE-truncated ORF2 plasmid; Lane 7, digested pVAX-tPA<sub>sp</sub>-PADRE-truncated ORF2 plasmid by the NheI restriction enzyme; Lane 8, digested pVAX-tPA<sub>sp</sub>-PADRE-truncated ORF2 plasmid by NheI and XhoI restriction enzymes and production of two expected fragments, a 2909-bp and a 1795-bp fragment; Lane 9, 1876-bp band in colony PCR test with T7 and BGH universal primers; B, Restriction Enzyme analyses and colony polymerase chain reaction results of three colonies containing pVAX-tPA<sub>sp</sub>-PADRE-truncated ORF2 (aa 112 - 660) plasmid; Lane M, 1 kb DNA marker; Lane 1, negative control; Lanes 2 - 4, 1876-bp band in colony PCR test; Lanes 5 - 7, digested pVAX-tPA<sub>sp</sub>-PADRE-truncated ORF2 (aa 112 - 660) linker plasmid by NheI and XhoI restriction enzymes and production of two expected fragments, a 2909-bp and a 1795-bp fragment.

Figure 4. A, Polymerase Chain Reaction Results of pVAX-Truncated ORF2 (aa 112 - 660) Expression Plasmid (without PADRE and tPA<sub>sp</sub> sequences); Lane M, 1 kb DNA marker; Lane 1, pVAX-truncated ORF2 (aa 112 - 660) plasmid; Lane 2, digested pVAX-truncated ORF2 (aa 112 - 660) plasmid by NheI restriction enzyme (4596 bp fragment); Lanes 3, digested pVAX-truncated ORF2 (aa 112 - 660) plasmid by NheI and XhoI restriction enzymes and production of two expected fragments, a 2909-bp and a 1693-bp fragment; Lanes 4, PCR product of truncated ORF2 (aa 112 - 660) gene (without PADRE and tPA<sub>sp</sub> sequences) with specific primers (1710 bp); Lanes 4, PCR product of truncated ORF2 (aa 112 - 660) gene (with PADRE and tPA<sub>sp</sub> sequences) with T7p and BGH primers (1876 bp); B, Colony Polymerase Chain Reaction Results of Colonies Containing the pVAX-Truncated ORF2 (aa 112 - 660) Expression Recombinant Plasmid; Lane M, 1 kb DNA marker; Lane 1, negative control; Lanes 2 - 9, 1774 bp band of pVAX-truncated ORF2 (aa 112 - 660) plasmid (without PADRE and tPA<sub>sp</sub> sequences) due to colony PCR assay with T7p and BGH universal primers; Lanes 2, 1876 bp band of pVAX-tPA<sub>sp</sub>-PADRE-ORF2 (aa 112 - 660) plasmid (with PADRE and tPA<sub>sp</sub> sequences) due to colony PCR assay with T7p and BGH primers as controls.
4.4. Expression and Confirmation of the Recombinant tPAsp-PADRE-Truncated ORF2 and Truncated ORF2 in Mammalian Cells

Confirmation of the truncated ORF2 gene expression in eukaryotic cells was performed at transcription and translation levels. The results of the RT-PCR assay that verify the transcription of HEV truncated ORF2 gene mRNA in transfected cells, with expression plasmids pVAX-tPa<sub>sp</sub>-PADRE-truncated ORF2 (aa 112 - 660) and pVAX-truncated ORF2 (aa 112 - 660), are shown in Figure 5. The size of the PCR product was 271 bp. Forty-eight hours after transfection, expression and production of truncated ORF2 protein in transfected cells was evaluated by Indirect Immunofluorescence Test (IFAT) using anti HEV polyclonal antibody. The results of the Immunofluorescence Test in transfected CHO and HEK293 cells with pVAX-tPa<sub>sp</sub>-PADRE-truncated ORF2 (aa 112 - 660), pVAX-truncated ORF2 (aa 112 - 660) and pVAX plasmid (as negative control) are shown in Figure 6.

Figure 5. A, Reverse Transcription-Polymerase Chain Reaction Amplification of Truncated ORF2 (aa 112-660) Gene From Transfected Cells and Electrophoresis on 2% Agarose Gel; Lane M, 100 bp DNA marker; Lane 1, RT-PCR product of truncated ORF2 (112 - 660) gene by F1478 and R1730 specific primers with 271-bp length, from CHO cells transfected with expression recombinant plasmid pVAX-truncated ORF2 (aa 112 - 660); Lane 2, RT-PCR assay of truncated ORF2 (112 - 660) gene from CHO cells transfected with pVAX plasmid (negative control); Lane 3, RT-PCR assay of truncated ORF2 (112 - 660) gene from untransfected cells (negative control); B, Reverse transcription-polymerase chain reaction amplification of tPa<sub>sp</sub>-PADRE-Truncated ORF2 (aa 112 - 660) Gene From Transfected Cells and Electrophoresis on 2% Agarose Gel; Lane M, 100 bp DNA marker; Lane 1 and 6, RT-PCR assay of truncated ORF2 gene from untransfected cells (negative control); Lanes 2 and 3, RT-PCR product of truncated ORF2 (aa 112 - 660) gene by F1478 and R1730 specific primers with 271-bp length, from CHO and HEK293 cells transfected with expression recombinant plasmid pVAX-tPa<sub>sp</sub>-PADRE-truncated ORF2 (aa 112 - 660); Lanes 4 and 5, RT-PCR assay of truncated ORF2 gene from cells transfected with the pVAX plasmid (negative control).
Figure 6. Identification of Truncated ORF2 Protein on Transfected Cells by the Indirect Fluorescent Antibody Test

A, Detection of HEV truncated ORF2 protein in CHO cells and B, HEK293 cells transfected with pVAX-PADRE-truncated ORF2 (aa 112 - 660) recombinant plasmid by the IFAT test. Detection of HEV ORF2 protein in CHO cells and C, HEK293 cells; D, transfected with pVAX-truncated ORF2 (aa 112 - 660) recombinant plasmid by the IFAT test.
5. Discussion

One strategy to enhance DNA vaccine potency is codon optimization, which is a generic technique to increase the efficiency of DNA expression vectors used in DNA vaccination, to achieve optimum expression of a foreign gene in the host’s cell system (28). Bradel-Tretheway et al. showed that gene codon-optimization is associated with a profound (10-100 fold) increase in protein expression in human (29A, HSG, K562) or hamster (CHO) cell lines (29). He et al. used Cos-7 cells to confirm the expression of the pJHEV ORF2 plasmid (14). In the present study, we evaluated the ORF2 expression in CHO and HEK293 cells by the IFA test. The results showed that the expression level of the recombinant plasmids was higher in transfected CHO cells than in HEK293 cells, yet a greater number of HEK293 cells was transfected. The results by several groups have clearly demonstrated that vector vaccines exploiting codon-optimized genes elicit higher levels of protein expression and humoral and cellular responses than DNA vaccine constructs encoding the corresponding wild-type gene (30-33).

Several reports and web-based programs have proposed algorithms for gene optimization on the basis of different calculation methods (34-36). In this study, the Vector NTI software was used for designing of the construct. Initially, a kozak sequence, a tissue plasminogen activator signal sequence and PADRE sequences were added to the N-terminal of the truncated ORF2 (112 - 660 aa) respectively. Subsequently, the construct was optimized based on mouse codon usage using the GenScript software to improve the expression of a truncated ORF2 DNA vaccine in mammalian cells. In wild-type ORF2 (112 - 660 aa), the Arg, Ser and Pro amino acid residues are encoded by codons rarely seen in mouse genes. By substituting high-usage codons for these rare codons without altering the amino acid sequences, we could increase the level of protein expression in mammalian cells.

Codon usage preference in a gene is determined by the codon adaptation index (CAI) and scores from zero to one (27). The designed genes with maximum CAI have high protein expression level (37). Narum et al. showed that increasing the rate of the CAI in an optimized gene plays an important role in enhancing gene expression (31). In this study, the score of CAI after codon optimization was 0.84, thus this is indicative of better chances of high-level protein expression. Any peak outside the 45% to 65% range of GC content will adversely affect transcriptional and translational efficiency, thus undesirable picks with high GC content were removed (Figure 2). Moreover, the negative CIS element with the nucleotide sequence GGTAG in 543 to 544 amino acid positions (splice site) of non-optimized ORF2 sequence was modified during the optimization process. Negative CIS elements are motifs that negatively regulate gene expression at the level of transcription and translation.

Another indicator of codon usage index that was introduced by Ikemura is frequency of optimal codon usage (Fop), which is also used to predict the level of expression (38). The FOP value of 100 shows the highest usage frequency for a certain amino acid in a specific expression organism. After analyzing the gene sequence of truncated ORF2, we found that almost 15% of codons showed a value less than 40 for frequency of occurrence in mouse genes. Such codons are associated with low levels of protein expression because of ribosome stalling and failed translation. After optimization, 56% were calculated to have a FOP value ranging from 91 to 100 (Figure 2).

Several reports indicate that the efficiency and magnitude of immune responses elicited by DNA vaccines are influenced by the secretion ability of the expressed antigen (39, 40). Secretion of the protein may increase antigen presentation in association with MHC class II, and thus increase the activation of antigen-specific CD4+ T-cells. Transient-transfection experiments have demonstrated that plasmids encoding a secreted form of the protein compared with plasmids encoding the non-secreted form have higher expression levels, and this is probably the most important factor involved in the enhancement of immunogenicity (22). The effect of the tPA leader sequence is outstanding for weakly immunogenic plasmids or when DNA is used at suboptimal doses or at a low dose number (21). Therefore, in this study the tissue plasminogen activator (tPA) leader sequence was placed upstream of PADRE-truncated ORF2 sequences to direct translation products to the secretory pathway, and to target the truncated ORF2 to the Class II processing pathway.

One strategy to enhance potency of a DNA-based vaccine is to induce CD4+ T helper cell immune responses. CD4+ T helper cells are known to play an important role in the generation of CD8+ T cell immune responses as well as memory T cell responses (41). Thus, design of an immunization regimen that induces CD4+ T cell immune responses is desirable. PADRE peptide can bind to variants of the human MHC class II molecules DR with high-affinity and induce helper-facilitated immunity in mice and lymphoproliferation in human peripheral blood mononuclear cell (PBMC) (23). Pan DR T helper epitopes (PADRE) peptide has been used in conjunction with different forms of vaccines to enhance the potency of vaccines in preclinical models (42, 43). Previous studies have shown that PADRE could be used as an adjuvant in prophylaxis and therapeutic vaccines. Therefore in the present study, similar to the study of Li et al., the PADRE sequence was designed for the N-terminal of truncated ORF2 (aa 112 - 660) (43).

Overall, results of this study showed that pVAX-tPA-PADRE-truncated ORF2 (aa 112 - 660) and pVAX-truncated ORF2 (aa 112 - 660) recombinant plasmids encoding the truncated form of HEV capsid protein were successfully expressed in eukaryotic cells. However, the immunogenicity and potency of these recombinant plasmids require to be
evaluated in vivo as two novel DNA vaccines in future investigations.

Acknowledgments

The authors would like to acknowledge the financial support of the infectious and tropical diseases research center of Ahvaz Jundishapur university of medical sciences, Ahvaz, Iran (grant No. 91113).

Footnotes

Authors’ Contribution: Reza Taherkhani designed the original idea and drafted the manuscript. Fatemeh Farshadpour and Reza Taherkhani developed and contributed equally to the performance of this study. Manochehr Makvandi participated in the laboratory evaluation and analyzed the data. Reza Taherkhani took the responsibility for the accuracy of the data. All authors read and approved the final manuscript.

Funding/Support: Financial support was provided by the infectious and tropical diseases research center of Ahvaz Jundishapur university of medical sciences, Ahvaz, IR Iran (grant No. 91113).

References

1. Emerson SU, Purcell RH. Hepatitis E virus. In: Knipe DM, editor. Fields Virology. 6th ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2013. pp. 2242-58.
2. Farshadpour F, Taherkhani R, Makvandi M. Prevalence of Hepatitis E Virus among Adults in South-West of Iran. Hepat Res Treat. 2015;7:959589. doi: 10.1556/2015.7.959589. [PubMed: 26997956]
3. Boccia D, Guthmann JP, Klovdal H, Hamid N, Tatsuyama C, Giclenkeici I, et al. Mortality of patients with hepatitis E among displaced persons in Darfur, Sudan. Clin Infect Dis. 2006;42(12):1679–84. doi: 10.1086/504322. [PubMed: 16705571]
4. Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology. 2007;46(2):474–8. doi: 10.1002/hep.21646. [PubMed: 17143058]
5. Taherkhani R, Farshadpour F. A new strategy for development of hepatitis E vaccine: Epitope-based vaccines. Pathogen Infect Dis. 2015;1: e9331. doi: 10.4103/2338-0920.159931.
6. Emerson SU, Purcell RH. Recombinant vaccines for hepatitis E. Trends Mol Med. 2001;7(10):462–6. doi: 10.1016/S1471-4914(01)00106-2. [PubMed: 11857521]
7. Tam AW, Smith MM, Guerra MF, Huang CC, Bradley DW, Fry KE, et al. Hepatitis E virus (HEV): Molecular cloning and sequencing of the full-length viral genome. Virology. 1999;263(2):320–31. [PubMed: 9267760]
8. Zhou YH, Purcell RH, Emerson SU. A truncated ORF2 protein contains the most immunogenic site on ORF2: Antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. Vaccine. 2005;23(24):3157–65. doi: 10.1016/j.vaccine.2004.12.020. [PubMed: 15872251]
9. Emerson SU, Clemente-Casares P, Molduddin N, Arankalle VA, Torian U, Purcell RH. Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay. J Gen Virol. 2006;87(3):689–704. doi: 10.1099/jgv.0.31545-0. [PubMed: 16746993]
10. Taherkhani R, Makvandi M, Farshadpour F. Development of enzyme-linked immunosorbent assays using 2 truncated ORF2 proteins for detection of IgG antibodies against hepatitis E virus. Ann Lab Med. 2014;34(2):118–26. doi: 10.3343/alm.2014.34.2.118. [PubMed: 24624447]
11. Taherkhani R, Farshadpour F, Makvandi M, Rajabi Memari H, Samarbaftzadeh AR, Sharifi N, et al. Cytokine profiles and cell proliferation responses to truncated ORF2 protein in Iranian patients recovered from hepatitis E infection. J Trop Med. 2015;2015:12523550. doi: 10.1155/2015/12523550. [PubMed: 26451419]
12. Li TC, Takeda N, Miyamura T, Matsuura Y, Wang JC, Engvall E, et al. Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J Virol. 2005;79(20):12999–3006. doi: 10.1128/JVI.79.20.12999-13006.2005. [PubMed: 16189002]
13. Taherkhani R, Farshadpour F, Makvandi M. Design and production of a multiepitope construct derived from hepatitis E virus capsid protein. J Med Virol. 2015;87(7):1225–34. doi: 10.1002/jmv.24247. [PubMed: 25784455]
14. He J, Hoffman SL, Hayes CG. DNA inoculation with a plasmid vector carrying the hepatitis E virus structural protein gene induces immune response in mice. Vaccine. 1997;15(3):357–62. [PubMed: 9142055]
15. Kamili S. Toward the development of a hepatitis E vaccine. Virus Res. 2011;161(1):393–100. doi: 10.1016/j.viruses.2011.05.008. [PubMed: 21620908]
16. Wang L, Zhuang H. Hepatitis E: An overview and recent advances in vaccine research. World J Gastroenterol. 2004;10(15):2517–26. [PubMed: 15259057]
17. Navon S, Pilpel Y. The role of codon selection in regulation of translation efficiency deduced from synthetic libraries. Genome Biol. 2011;12(2):R12. doi: 10.1186/gb-2011-12-2-r12. [PubMed: 21284855]
18. Maertens B, Spriestersbach A, von Groll U, Roth K, Kubicek J, et al. Gene optimization mechanisms: A multi-gene study reveals a high success rate of full-length human proteins expressed in E. coli. Protein Sci. 2010;19(7):1312–26. doi: 10.1002/pro.408. [PubMed: 20506237]
19. Supié F, Smuc T. On relevance of codon usage to expression of synthetic and natural genes in E. coli. Nucleic Acids Res. 2010;38(3):3129–34. doi: 10.1093/nar/gkp1277. [PubMed: 20426064]
20. Watts AM, Kennedy RC. DNA vaccination strategies against infectious diseases. Int J Parasitol. 1999;29(6):819–41. doi: 10.1016/S0020-7519(99)00143-0. [PubMed: 10576567]
21. Baldwin SL, D’Souza CD, Orme IM, Liu MA, Huygen K, Denis O, et al. Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tuberc Lung Dis. 1999;79(4):251–9. doi: 10.1054/tlbd.1999.0196. [PubMed: 10692994]
22. Zhu W, Howard A, Kelley C, Delogu G, Collins F, Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun. 1999;67(9):4780–6. doi: 10.1128/IAI.67.9.4780-6.99. [PubMed: 10456931]
23. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;9(5):576–84. [PubMed: 7895616]
24. Ishioka GY, Files J, Hermanson G, Livingston B, Crimi C, Qin M, et al. Utilization of MHC class I transgenic mice for development of minigenes DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol. 1999;162(7):3995–25. doi: 10.4049/jimmunol.162.7.3995. [PubMed: 10201910]
25. Farshadpour F, Taherkhani R, Makvandi M, Rajabi Memari H, Samarbafzadeh AR. Codon-Optimized Expression and Purification of Truncated ORF2 Protein of Hepatitis E Virus in Escherichia coli. Jundishapur J Microbiol. 2014;7(7):12161. doi: 10.5812/jmm.12161. [PubMed: 25568796]
26. Taherkhani R, Farshadpour F, Makvandi M, Samarbafzadeh AR, Cloning of flic Gene From Salmonella typhimurium in the Expression Vector pVAXI and Evaluation of its Expression in Eukaryotic Cells. Jundishapur J Microbiol. 2014;7(11):e23351. doi: 10.5812/jmm.23351. [PubMed: 25774273]
27. Sharp PM, Li WH. The codon Adaptation Index—a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 1987;15(3):859–66. [PubMed: 3543735]
28. Sandhu KS, Pandey S, Maiti S, Pillai B. GASCO: genetic algorithm simulation for codon optimization. In Silico Biol. 2008;8(2):387–92. [PubMed: 18928205]
29. Bradel-Tretheway BG, Zhen Z, Dewhurst S. Effects of codon-optimization on protein expression by the human herpesvirus 6 and 7 U51 open reading frame. *J Virol Methods.* 2000;81(1-2):145–56. [PubMed: 12880930]

30. Deml I, Bojak A, Steck S, Graf M, Wild J, Schirmbeck R, et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. *J Virol.* 2001;75(21):10991-1000. doi: 10.1128/JVI.75.21.10991-1000.2001. [PubMed: 11602739]

31. Narumi DL, Kumar S, Rogers KO, Fuhrmann SR, Liang H, Oakley M, et al. Codon optimization of gene fragments encoding *Plasmodium falciparum* merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. *Infect Immun.* 2001;69(12):7250–3. doi: 10.1128/IAI.69.12.7250-7253.2001. [PubMed: 11705894]

32. Simabuco FM, Tamura RE, Carromeu C, Farinha-Arcieri LE, Viertur AM. Gene optimization leads to robust expression of human respiratory syncytial virus nucleoprotein and phosphoprotein in human cells and induction of humoral immunity in mice. *J Virol Methods.* 2003;111(2):145–56. doi: 10.1016/j.jviromet.2003.10.020. [PubMed: 16376569]

33. Ikemura T. Correlation between the abundance of Escherichia coli transfer RNAs and the occurrence of the respective codons in its protein genes. *J Mol Biol.* 1981;146(1):1–21. [PubMed: 6167726]

34. Costa SM, Paes MV, Barreto DF, Pihao AT, Barth OM, Queiroz JL, et al. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural1 (NS1) gene fused to the tissue plasminogen activator signal sequence. *Vaccine.* 2006;24(2):195–205. doi: 10.1016/j.vaccine.2005.07.059. [PubMed: 16122850]

35. Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. *J Virol.* 2008;82(1):1293–7. doi: 10.1128/JVI.01293-08. [PubMed: 18789973]

36. Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. *Annu Rev Immunol.* 2006;24:519–40. doi: 10.1146/annurev.immunol.24.021704.115825. [PubMed: 16551258]

37. Alexander J, del Guercio MF, Frame B, Maewal A, Sette A, Nahm MH, et al. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). *Vaccine.* 2004;22(19):2362–7. doi: 10.1016/j.vaccine.2003.11.061. [PubMed: 15193395]

38. Li P, Cao RB, Zheng QY, Liu J, Li Y, Wang EX, et al. Enhancement of humoral and cellular immunity in mice against Japanese encephalitis virus using a DNA prime-protein boost vaccine strategy. *Vet J.* 2010;183(2):200–6. doi: 10.1016/j.tvjl.2008.09.019. [PubMed: 19908134]